Cell line · CVCL_0307
Papers33
4 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
1 to 20 of 33
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| A Calcipotriol-Responsive ZF10-ΔVDR Switch for Mammalian Transgene Regulation with Topical Induction In Vivo. | Genes (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Combined treatment using repurposed synthetic peptide desmopressin and bevacizumab as a potential antiangiogenic strategy in osteosarcoma. | Front Med (Lausanne) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Divergent Rickettsia species exhibit distinct mechanisms of actin-based motility. | J Cell Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Global analysis of cancer cell responses to USP9X inhibition. | EMBO J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting BMP and TAZ/TEAD mechanotransduction pathways impairs acute myeloid leukemia chemoresistance. | Leukemia | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Tumor-Derived Exosomal TAGLN2 Promotes Metastasis by Inducing Vascular Permeability and Angiogenesis via the NRP1/SEMA4D/YAP Axis. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Exploiting porphyrin metabolism to inhibit angiogenesis. | Angiogenesis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Design of RGD-functionalized GSH-responsive pegylated polymeric protacs for selective BRD4 degradation and EndMT-driven cardiac fibrosis inhibition. | J Nanobiotechnology | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CGRP Enhances the Regeneration of Bone Defects by Regulating Bone Marrow Mesenchymal Stem Cells Through Promoting ANGPTL4 Secretion by Bone Blood Vessels. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| LncRNA DANCR Activates p38/mTOR-Mediated Autophagy via ANXA2 to Exacerbate Oxygen-Induced Retinal Neovascularization in Mice. | FASEB J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| NIR Ratiometric Fluorescent Antibody-Drug Conjugate for Metastatic Ovarian Cancer Theranostics and Treatment Response Monitoring. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Biomimetic Fibrinogen Nanofiber Scaffolds for Vascular Hematopoietic Stem Cell Niche Engineering. | Adv Healthc Mater | 2026 | Its Methods give the RRID and name the line | PubMed | |
| YAP1::TFE3 mediates endothelial-to-mesenchymal plasticity in epithelioid hemangioendothelioma. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| In vitro exploration of drug-induced thrombotic microangiopathies: clues of diverse endothelial activation pathways respective to interferon-β1a, ciclosporin A, and gemcitabine exposure. | Front Pharmacol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Evaluation of dasatinib and ponatinib for the control of CD123 CAR-T cell functionalities. | Mol Ther Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Oncostatin M induces epigenetic reprogramming in renal cell carcinoma-associated endothelial cells. | Commun Biol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Pericytes promote metastasis by regulating tumor local vascular tone and hemodynamics. | Nat Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The role of IGF-2 and its variants in enhancing endothelial migration and angiogenesis. | Front Cell Dev Biol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Characterization of the Temporal Dynamics of the Endothelial-Mesenchymal-like Transition Induced by Soluble Factors from Dengue Virus Infection in Microvascular Endothelial Cells. | Int J Mol Sci | 2025 | Its Methods give the RRID and name the line | PubMed | |
| miR-497 Target Gene Regulatory Network in Angiosarcoma. | Mol Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0307/papers